semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Women or men with histologic evidence of invasive breast cancer (ductal, lobular or mixed disease) Surgical resection including breast conserving surgery or modified radical mastectomy or simple mastectomy, within the last four months Axillary lymph nodes assessed for tumor by: (i) sentinel node biopsy, or (ii) axillary node dissection, or (iii) both Axillary lymph node assessment negative for cancer, or positive only for micrometastases (i.e., cancer <2mm by H&E stain) Tumor is estrogen receptor (ER) positive Receiving or to receive adjuvant endocrine therapy (i.e., tamoxifen or aromatase inhibitor) Being considered for adjuvant chemotherapy  Axillary lymph node positive for cancer Patients with inoperable locally advanced breast cancer Metastatic breast cancer, including local ipsilateral recurrence HER2 neu positive Physician/Patient unwilling to comply with study protocol Inability to provide informed consent (e.g. dementia or severe cognitive impairment)
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Colorectal Cancer Histologically or cytologically proven adenocarcinoma of the colon expressing non-mutated (wild-type) KRAS Progressive metastatic disease after first-line treatment with chemotherapy alone: based on 5-FU (iv or per os) with irinotecan or oxaliplatin associated to bevacizumab Prior adjuvant chemotherapy (of the primary tumor) with fluoropyrimidine and oxaliplatin is allowed if the time interval between the end of this chemotherapy and the beginning of the first-line metastatic treatment is ≥ 6 months Measurable disease (at least one measurable metastatic lesion) according to the V1.1 (the lesion should not be located in a previous field of radiation) Previous radiotherapy is authorized if discontinued ≥ 15 days prior to randomization and if the measurable metastatic lesions are outside the radiation area Sites of disease evaluated within 28 days prior to randomization with thoracic-abdominal-pelvic CT scan (or abdominal-pelvic MRI plus Chest Xray) Age ≥18 years Patient with ECOG 0 or 1 Life Expectancy ≥ 3 months Hematologic function (polynuclear neutrophiles ≥ 1.5.109/L ; platelets ≥ 100.109/L ; hemoglobin ≥ 9 g/dL  Known meningeal or brain metastases Pre-treatment with anti-EGFR Specific contraindication or known hypersensitivity to one treatment product Patient with known allergy or hypersensitivity to monoclonal antibodies (bevacizumab, cetuximab Clinically significant affection of the coronaries or myocardial infarction within 6 months prior to inclusion Peripheral neuropathy of grade > 1 (CTCAE scale version 4.0) Known depletion of the dihydropyrimidine dehydrogenase (DPD) Acute intestinal obstruction or sub-obstruction, history of inflammatory intestinal disease or extended resection of the small intestine. Presence of a colic prosthesis Uncontrolled Arterial hypertension (systolic pressure > 150 mmHg and/or diastolic pressure > 100 mmHg with and without antihypertensive medication. Patients with high hypertension are eligible if antihypertensive medication lowers their arterial pressure to the level of acceptability specified by the criteria History of hypertensive crisis or hypertensive encephalopathy
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-85.0,  Knee Osteoarthritis patients undergoing elective bilateral staged total knee arthroplasty at a 1-week interval under spinal anesthesia age <=85 American Society of Anesthesiologists physical status of I to II  any contraindication to spinal anesthesia or femoral nerve block such as coagulopathy; conversion to general anesthesia; preexisting pain syndrome; abnormal liver function or renal test results; severe heart, liver, or renal disease; history of stroke or neurologic deficits; psychiatric disorder; chronic opioid use; drug dependency; allergy to study medications; inflammatory joint disease; previous surgery on or trauma of the knee; difference in preoperative VAS score of ≥ 20 (at rest and at maximum knee flexion) between each side of the knee; body mass index of ≥ 40 kg/m2; and inability to comprehend the VAS or to use patient-controlled analgesia (PCA
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Infiltrating Bladder Urothelial Carcinoma Muscle invasive urothelial cancer (front line or following the progression of a superficial tumor), pT2-pT3 stage without lymphatic impairment (N0) and without detectable metastases (M0). An optimal macroscopic resection (TURB) have to be performed The proof of invasive tumor to the muscle should be brought by a transurethral resection under anaesthesia less than 8 weeks before or, in the absence, by superficial biopsies and formal imaging. Multiples biopsies in the bladder must also be performed Age ≥ 18 years Life expectancy ≥ 6 months Kanorfsky index ≥ 70 % (WHO 0, 1, 2) Biological neutrophils ≥ 1500/mm3, Platelets ≥ 100 000/mm3, haemoglobin ≥ 10 g/dl, creatinine clearance > 60 ml/mn No distant metastases (Thorax, abdomen, and pelvic CT-scan, bone scan) Efficient contraception for premenopausal women, maintained during the whole treatment and up to two months after the completion of radiotherapy No radiotherapy or chemotherapy history except for in situ bladder lesions No carcinological history except for non melanoma skin tumours, in situ uterine cervix cancer  Bladder tumors without any muscle infiltration Epidermoid carcinoma or adenocarcinoma Distance metastases or extrapelvic node positivity Severe digestive history (ulcerative colitis, complicated diverticulitis) Pregnancy and breast feeding
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Women with histologically proven invasive breast cancer and no distant metastases and Lymphnode negative and a clinical tumor classification of T2 (≥3.5cm)-T4 or with 1-3 positive lymph nodes and a clinical tumor classification of T2-T4 DCIS or LCIS are allowed in addition to invasive cancer at T2 or T3 level Age ≥ 18 years At least one lesion that can be accurately measured in two dimensions utilizing mammogram, ultrasound, or MRI images to define specific size and validate complete pathologic response Adequate bone marrow reserves (neutrophil count >1.5 x109 /l and platelet count >100 x109/l), adequate renal function (serum creatinine ≤ 1.5 x upper limit of normal) and hepatic function (ALAT, ASAT ≤ 2.5 x upper limit of normal, alkaline phosphatase ≤ 2.5 x upper limit of normal and total bilirubin ≤ 2.0 x upper limit of normal) Signed informed consent of the patient  Any patient with confirmed metastatic disease. Patients with inflammatory breast cancer Tumor sample shipped to Agendia with ≤ 30% tumor cells or that fails Quality Assurance or Quality Control criteria Patients who have had any prior chemotherapy, radiotherapy, or endocrine therapy for the treatment of breast cancer Any serious uncontrolled intercurrent infections, or other serious uncontrolled concomitant disease
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Patients aged over 18 years old with invasive breast cancer with an indication of SN procedure as recommended by Saint-Paul de VENCE in 2005 amended in 2009 T1-2 breast cancer Patients having social security coverage  Patient under the age of 18 Patient who had neoadjuvant chemotherapy Patient who had had radiotherapy to the ipsilateral axilla or breast Pregnant patient Patients who do not speak French Patients refusing to participate in the study Simultaneous participation in another research period of
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Breast Cancer Signed informed consent 2. Social security coverage 3. Age between 18 and 80 years 4. Histologically proven breast cancer, regardless of histological type or molecular subtype (triple negative, hormone-receptor positive, HER2+++), including inflammatory forms 5. Localised breast cancer with or without axillary or subclavicular lymph node involvement 6. Absence of bone or visceral metastasis on further evaluation (bone scintigraphy, chest X-ray, abdominal echocardiography or CT scan of the thorax, abdomen and pelvic area) 7. Treatment by neoadjuvant chemotherapy (treatment protocol at physician's discretion) 8. Patient amenable to receiving adjuvant therapy (chemotherapy, radiotherapy, hormone therapy, targeted therapy) 9. Breast surgery (breast-sparing or not) planned after neoadjuvant chemotherapy  Metastatic breast cancer 2. Neoadjuvant radiotherapy 3. Patient not amenable to surgery 4. Ongoing therapy for any other type of cancer 5. Legal incapacity (incarceration or persons under legal guardianship) 6. Patient unable to sign the informed consent or unable to attend medical follow-up for geographical, social or mental reasons
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Metastatic Breast Cancer Postmenopausal women with HER2-, HR+ locally advanced or metastatic breast cancer Progression on or after endocrine treatment Measureable disease as per ECOG 0, 1 or 2  Evidence of CNS or leptomeningeal metastases Previous treatment with fulvestrant Previous chemotherapy for locally advanced or metastatic breast cancer Cirrhosis or chronic active/persistent hepatitis Other protocol-defined inclusion/
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Conditions or Focus of Study: *FDAAA (Enter 1 to 5 Items) Male or Female > 18 years, 2. Newly diagnosed stage I-IV breast cancer which is defined to meets any one of the following clinical or pathological staging (version 6.0 AJCC classification17) in Appendix B. 3. No prior therapy (other than surgery) for current disease, 4. Written informed consent (if required by local regulations)  Unable to receive definitive treatment 2. Unable to attend regular follow-up visit
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Breast Cancer Breast Cancer Stage II-III Informed consent form signed by the patient to accept study enrollment Female with pathologically confirmed diagnosis of primary invasive operable breast cancer, stage IIa-IIIc (6th edition of the AJCC Cancer Staging Manual), with tumors ≥ 2cm. Triple negative phenotype patients (RE and PR of less than 1% of stained cells by IHQ, IHC for HER2 of 0-1+ or ISH negative if 2/3+), according to local laboratory Age 18-75 years Adequate performance status (ECOG <2) Adequate renal and liver function and bone marrow reserve  Clinical or radiologic evidence of Metastatic disease Prior or concurrent anti-cancer therapy for current disease (hormone therapy, chemotherapy, radiotherapy, immunotherapy) Prior therapy with taxanes, anthracyclines or carboplatin for any malignancy Contraindication for study drugs (docetaxel or carboplatin) Serious concomitant systemic disorder that in the opinion of the investigator would compromise the patient's ability to complete the study, or have any other disease that could be worsened by chemotherapy or other potential support therapies
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Locally Advanced Malignant Neoplasm Women older than 18 years old and younger than 70 years old Invasive breast cancer confirmed by core biopsy, any histology Tumor ≥2 cm and/or lymph node positive (proven by FNA)(T2-4b, N0-3, M0) Must have ER/PR positive and HER2 negative Must have full staging and extent disease and clinically and radiographically tumor measure Without previous treatment for breast cancer (including surgery, hormonotherapy or chemotherapy) Normal liver, kidney and blood tests Performance Status ECOG 0-2 o Karnofsky ≥70% Fasten glucose levels <125 mg/dl Signed consent  Previous use of metformin for any indication Presence of Diabetes Mellitus
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Infiltrating Bladder Urothelial Carcinoma Age ≥18 years Histologically confirmed primary transitional cell carcinoma (TCC) of the urinary bladder T2 to T4 disease, N0 M0 determined by computerised tomography (CT) imaging and biopsy or transurethral resection Eastern Co-operative Oncology Group (ECOG) Performance status 0 or 1 Glomerular filtration rate (GFR) ≥60ml/min Written, informed consent  ECOG Performance Status ≥ 2 Lymph node involvement or metastatic disease Prior surgery (except transurethral resection of bladder tumour), radiation, che-motherapy, or other anti-cancer therapy within 4 weeks prior to enrolment Active Grade ≥2 peripheral neuropathy Active secondary cancers History of severe hypersensitivity reaction (≥Grade 3) to polysorbate 80 containing drugs Other concurrent serious illness or medical conditions Inadequate organ function as evidenced by peripheral blood counts at enrolment Electrocardiogram (ECG) evidence of uncontrolled cardiac arrhythmias, angina pectoris, and/or hypertension, history of congestive heart failure, or myocardial infarction within last 6 months Uncontrolled diabetes mellitus
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Lung Cancer Women or men > age 18. Ability to give informed consent Archived tumor tissue must be available for genetic analysis. Patients with early-stage breast cancer Histologic documentation of invasive breast cancer by core needle or incisional biopsy. The invasive cancer must be either triple-negative with both estrogen and progesterone receptor staining present in fewer than 10% of invasive cancer cells by IHC, and HER2-negative defined as IHC 0-1+, or with a FISH ratio of <1.8 if IHC is 2+ or if IHC has not been done. or *HER2-positive with IHC 3+ or a FISH ratio of >2.2. Clinical Stage II-III invasive breast cancer with the intent to treat with pretreatment mammography, ultrasound, and breast MRI for staging pretreatment axillary staging neoadjuvant treatment with DNA-damaging chemotherapy (with or without HER2 directed therapy) post-chemotherapy breast MRI surgical resection of the primary tumor with an axillary dissection for one or more positive nodes after neoadjuvant chemotherapy Patients with multicentric or bilateral disease are eligible if the target lesion(s) meet the other criteria. No prior chemotherapy, endocrine therapy, or radiotherapy with therapeutic intent for treatment of a prior malignancy is allowed. Patients with locally advanced or metastatic breast cancer Histologic documentation or history of invasive breast cancer by core needle or incisional biopsy, or by surgical resection. ER/PR/HER2 status may be determined using any breast tumor specimen acquired at any point during a given patient's disease history (i.e., archived tumor). The invasive cancer must be either: *triple-negative with both estrogen and progesterone receptor staining present in fewer than 10% of invasive cancer cells by IHC, and HER2-negative defined as IHC 0-1+, or with a FISH ratio of <1.8 if IHC is 2+ or if IHC has not been done. or *HER2-positive with IHC 3+ or a FISH ratio of >2.2. Clinical Stage III-IV invasive breast cancer not amenable to curative surgical resection, with intent to treat with if tumor is triple-negative, treatment with DNA-damaging chemotherapy as per standard of care in the first-line setting for advanced/metastatic disease if tumor is HER2+, treatment with DNA-damaging chemotherapy, HER2-directed therapy, or a combination as per standard of care in any setting for advanced/metastatic disease
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Breast Cancer Patients with breast cancer